Chromophore-modified bis-benzo[g]indole carboxamides: Synthesis and antiproliferative activity of bis-benzo[g]indazole-3-carboxamides and related dimers

Farmaco

Volumn 58, Issue 9, 2003, Pages 749-763

  Pinna, Gérard A ^a   Pirisi, Maria A ^a   Mussinu, Jean Mario ^a   Murineddu, Gabriele ^a   Loriga, Giovanni ^a   Pau, Amedeo ^a   Grella, Giuseppe E ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cytotoxic activity; Tricyclic pyrazole; Viscosity

Indexed keywords

AMIDE; ANTINEOPLASTIC AGENT; N3 [2 [2 [[[1 (2,4 DICHLOROPHENYL) 1H BENZ[G]INDAZOL 3 YLCARBONYL]AMINO]ETHYL]METHYLAMINO]ETHYL] 1 (2,4 DICHLOROPHENYL) 1H BENZ[G]INDAZOLE 3 CARBOXAMIDE; N3 [2 [[2 [(1 PHENYL 1,4 DIHYDROINDENO[1,2 C]PYRAZOL 3 YLCARBONYL)AMINO]ETHYL]METHYLAMINO]ETHYL] 1 PHENYL 1,4 DIHYDROINDENO[1,2 C]PYRAZOLE 3 CARBOXAMIDE; N3 [2 [[2 [(1 PHENYL 1H BENZ[G]INDAZOL 3 YLCARBONYL)AMINO]ETHYL]METHYLAMINO]ETHYL] 1 PHENYL 1H BENZ[G]INDAZOLE 3 CARBOXAMIDE; N3 [2 [[2 [(1H BENZ[G]INDAZOL 3 YLCARBONYL)AMINO]ETHYL]METHYLAMINO]ETHYL] 1H BENZ[G]INDAZOLE 3 CARBOXAMIDE; N3 [2 [[2 [[1 (2,4 DICHLOROPHENYL) 1,4 DIHYDROINDENO[1,2 C]PYRAZOL 3 YLCARBONYL]AMINO]ETHYL]METHYLAMINO]ETHYL] 1 (2,4 DICHLOROPHENYL) 1,4 DIHYDROINDENO[1,2 C]PYRAZOLE 3 CARBOXAMIDE; N3 [3 [[3 [(1 PHENYL 1,4 DIHYDROINDENO[1,2 C]PYRAZOL 3 YLCARBONYL)AMINO]PROPYL]METHYLAMINO]PROPYL] 1 PHENYL 1,4 DIHYDROINDENO[1,2 C]PYRAZOLE 3 CARBOXAMIDE; N3 [3 [[3 [(1 PHENYL 1H BENZ[G]INDAZOL 3 YLCARBONYL)AMINO]PROPYL]METHYLAMINO]PROPYL] 1 PHENYL 1H BENZ[G]INDAZOLE 3 CARBOXAMIDE; N3 [3 [[3 [(2 METHYL 2H BENZ[G]INDAZOL 3 YLCARBONYL)AMINO]PROPYL]METHYLAMINO]PROPYL] 2 METHYL 2H BENZ[G]INDAZOLE 3 CARBOXAMIDE; N3 [3 [[3 [[1 (2,4 DICHLOROPHENYL) 1,4 DIHYDROINDENO[1,2 C]PYRAZOL 3 YLCARBONYL]AMINO]PROPYL]METHYLAMINO]PROPYL] 1 (2,4 DICHLOROPHENYL) 1,4 DIHYDROINDENO[1,2 C]PYRAZOLE 3 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; MALE; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; VISCOSITY;

EID: 0141564699     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(03)00131-9     Document Type: Article

References (18)

1. Calabresi P., Chabner B.A. Chemotherapy of neoplastic diseases. Hardmann J.G., Limbird L.E. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 2001;1381 McGraw-Hill Medical Publishing Division, New York.
2. Silverman R.B. The Organic Chemistry of Drug Design and Drug Action. 1992;220 Academic Press, Inc., Harcourt Brace Jovanovich Publishers, San Diego.
3. Denny W.A. Foye W.O. Cancer Chemotherapeutic Agents. 1995;218-239 American Chemical Society, Washington, DC.
4. Pinna G.A., Pirisi M.A., Grella G.E., Gherardini L., Mussinu J.M., Paglietti G., Ferrari A.M., Rastelli G. Synthesis and cytotoxicity of bis(benzo[g]indole-3-carboxamides) and related compounds. Arch. Pharm. Pharm. Med. Chem. 334:2001;337-344.
5. Hamilton R.W. The antiarrhythmic and antinflammatory activity of a series of tricyclic pyrazoles. J. Heterocyclic Chem. 13:1976;545-553.
6. 13C-chemical shift prediction rules for 1,3,5-trisubstituted pyrazoles. Heterocycles. 55:(2):2001;331-351.
7. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83:1991;757-766.
8. Paull K.D., Shoemaker R.H., Hods L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., Boyd M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and compare algorithm. J. Natl. Cancer Inst. 81:1989;1088-1092.
9. Boyd M.R., Paull K.D., Rubinstein L.R. Valeriote F.A., Corbett T., Baker L. Cytotoxic Anticancer Drugs: Models and Concept for Drug Discovery. 1992;11 Kluwer Academic Publishers, Amsterdam.
10. Plowman J., Dykes D.J., Hollingshead M., Simpson-Herren L., Alley M.C. Human Tumor Xenograft Models in NCI Drug Development. Teicher B. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval. 1997;101 Humana Press Inc, Totowa, NJ.
11. Hirata K., Araya J., Nakaike S., Kitamura K., Ishida T. Side chain-dependent binding of antitumor indoloquinoxaline derivatives to DNA: comparative spectroscopic and viscometric measurements. Chem. Pharm. Bull. 49:2001;44-48.
12. 4a,10a-dodecahydrophenanthrene, cis-9-methyl-1-decalone and other cyclic ketones. J. Am. Chem. Soc. 68:1946;2580-2584.
13. Von Auwers K., Enbergs F. Bestimmung der Struktur von Derivaten des Dihydronaphto-pyrazols. J. Prakt. Chem. 134:1932;97-104.
14. Doria G., Isetta A.M., Ferreccio R., Ferrari M., Fornasiero M.C., Tibolla M., Rossi M., Carlini O., Motta P., Magistrelli M., Tammiso M., D'Antuono G., Mameli M., Trizio D. Synthesis and immunomodulating activity of condensed N-aryl-2-cyano-3-oxo-3-pyrazolyl-propanamides. Farmaco. 46:1991;843-860.
15. 2 cannabinoid receptors. Bioorg. Med. Chem. 11:2003;251-263.
16. Piozzi F., Passannanti S. Sintesi di derivati idro-indazolici. Gazz. Chim. Ital. 100:1970;639-649.
17. G.D. Hawkins, D.J. Giesen, G.C. Lynch, C.C. Chambers, I. Rossi, J.W. Storer, D. Rinaldi, D.A. Liotard, C.J. Cramer, D.G. Truhlar, AMSOL 6.5.3. (September 1998).
18. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J., Bokesch H., Kenney S., Boyd M. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112.